Novartis abandons BioArctic brain-delivery pact after strategic review
Novartis has ended its neuroscience collaboration with BioArctic barely 14 months after signing the agreement, stepping away from an alliance that had the potential to deliver up to $772 million in milestones and tiered mid-single digit royalties. The termination removes one of the more visible bets in Novartis’ effort to solve one of drug development’s most stubborn barriers: getting large biologic medicines across the blood-brain barrier and into the central nervous system in therapeutically meaningful amounts.
The deal was signed in August 2025 and paired BioArctic’s BrainTransporter technology with a Novartis antibody against an undisclosed neurodegeneration target. At the time, the companies framed the collaboration as a way to use transferrin receptor biology to promote brain uptake and improve systemic delivery of novel agents. In practical terms, the attraction was straightforward: many antibody-based therapies have strong target specificity on paper, yet fail in the clinic because the brain keeps most of the molecule out.
Novartis said the termination followed a recent review of early research priorities aimed at concentrating effort where it can have the greatest impact. The company said the decision was not driven by safety or efficacy concerns. That distinction matters because it places the exit in the realm of portfolio triage rather than a clinical failure in the platform itself. The collaboration still leaves BioArctic with the $30 million upfront payment, but the larger economics of the arrangement have now fallen away.
The biology behind the deal remains compelling. The blood-brain barrier is not a single wall but a highly selective endothelial interface designed to protect neural tissue from toxins and pathogens. The same gatekeeping function frustrates development in diseases such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, and amyotrophic lateral sclerosis, where the most potent systemic drugs often arrive at the target tissue in amounts too low to matter. Transferrin receptor shuttle systems attempt to exploit an endogenous transport pathway to move therapeutic cargo into the brain, a strategy that has drawn broad interest across the industry.
The setback also fits a broader pattern at Novartis. Earlier this year, Bob Baloh, global head of neuroscience at Novartis Biomedical Research, said the company does not view the BBB problem as one that will yield to a single universal fix. Instead, the company expects to need a toolbox of technologies and continues to look for alternative ways to cross the barrier. In that context, dropping one external platform does not signal retreat from neuroscience so much as a sharper internal sorting of which delivery systems deserve continued capital.
A direct line connects this decision to the company’s other recent moves. In September, Novartis paid $125 million to exercise an option to acquire Sironax’s brain delivery platform. That transaction suggests the Swiss drugmaker is still actively shopping for approaches that might improve central nervous system exposure, even as it trims other experiments that no longer fit the current research hierarchy. The two moves together point to a company that is not abandoning brain drug delivery, but pruning aggressively while it searches for a platform with clearer translational promise.
BioArctic’s position is less strained than the headline might suggest. The company keeps the upfront cash and still has other large-pharma partnerships in place, including an Alzheimer’s disease pact with Bristol Myers Squibb and a separate BrainTransporter collaboration with Eli Lilly. For a platform company, those relationships matter because they preserve optionality. A single terminated deal can narrow the path to future milestones, yet it does not erase the underlying technology’s appeal if other partners continue to advance it.
The larger commercial backdrop is less forgiving. Novartis’ pipeline has faced scrutiny after failed phase 3 trials for the antibody-oligonucleotide conjugate del-desiran in a rare muscle-wasting disease and for the cardiovascular drug pelacarsen. In that setting, every external program is likely to be judged against a stricter internal standard: not whether the science is interesting, but whether it can be translated into a differentiated asset with a realistic path to approval and commercial return. A neuroscience delivery platform that looks elegant in discovery can still lose out to other programs once portfolio math hardens.
The decision also says something about the current state of brain drug development. Investors and drugmakers have long hoped that delivery platforms would unlock the therapeutic potential of biologics in neurology, but the field has repeatedly shown how difficult it is to move from mechanism to patient benefit. High affinity for a transport receptor does not automatically translate into optimal tissue distribution, and increasing brain entry can bring new questions about peripheral exposure, receptor saturation, and dose selection. Those issues are part of why companies often pursue several different shuttle or transport strategies at once instead of betting on a single route.
For BioArctic, the immediate consequence is financial rather than scientific. The company loses the prospect of a large milestone stream tied to Novartis development progress, and with it a potential validation event that could have reinforced BrainTransporter’s standing in the market. For Novartis, the move frees attention and capital for other neuroscience assets, including the platform work it continues to pursue through Sironax and other internal or external programs. What remains unresolved is not whether brain delivery is important, but which technology can improve central nervous system exposure well enough to justify the scale of investment that these collaborations require.